Neoadjuvant Chemotherapy Flashcards
0
Q
What were the limitations to EORTC study?
A
The progression free survival and OS was 20 months lower than the reported US trials (30 months versus 50 months). The difference maybe because high-risk patients and international trial, or interval debulking may not have been optimal.
1
Q
What is the data for Neil asking chemotherapy?
A
And RCT phase 3 trial assessed neoadjuvant chemotherapy for three cycles followed by interval debulking , followed by three more cycles versus upfront surgery showed equivalent overall survival of 30 months.
